###begin article-title 0
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma
###end article-title 0
###begin p 1
###xml 102 123 102 123 <email xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">j.a.mitchell@ic.ac.uk</email>
 Correspondence: Cardiac Medicine, NHLI, Imperial College, Dovehouse St., London SW3 6LY, UK. E-mail: j.a.mitchell@ic.ac.uk
###end p 1
###begin p 2
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 457 460 457 460 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 647 655 647 655 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 715 718 715 718 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 897 900 897 900 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 719 723 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
###xml 956 961 <span type="species:ncbi:9606">human</span>
###xml 1088 1096 <span type="species:ncbi:9606">patients</span>
###xml 1401 1409 <span type="species:ncbi:9606">patients</span>
Cyclooxygenase (COX) -1 and COX-2 are expressed in airway cells, where their activities influence functions such as airway hyperreactivity. Clinical data show that mixed COX-1/COX-2 inhibitors such as aspirin, but not COX-2 selective inhibitors such as rofecoxib, induce bronchoconstriction and asthma in sensitive individuals. This anomaly has not yet been explained. Here, we have used tissue from genetically modified mice lacking functional COX-1 (COX-1-/-), as well as airway tissue from "aspirin-sensitive" and control patients to address this issue. Bronchi from wild-type mice contained predominantly COX-1 immunoreactivity and contracted in vitro in response to acetylcholine and U46619. Bronchi from COX-1-/- mice were hyperresponsive to bronchoconstrictors. Inhibitors of COX (naproxen, diclofenac, or ibuprofen) increased bronchoconstriction in tissue from wild-type but not from COX-1-/- mice. Cells cultured from aspirin-sensitive or control human donors contained similar levels of COX-1 and COX-2 immunoreactivity. COX activity in cells from aspirin-sensitive or tolerant patients was inhibited by aspirin, SC560, which blocks COX-1 selectively, but not by rofecoxib, which is a selective inhibitor of COX-2. These observations show that despite the presence of COX-2, COX-1 is functionally predominant in the airways and explains clinical observations relating to drug specificity in patients with aspirin-sensitive asthma.-Harrington, L. S., Lucas, R., McMaster, S. K., Moreno, L., Scadding, G., Warner, T. D., Mitchell, J. A. COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma.
###end p 3
###begin p 4
###xml 0 33 0 33 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Cyclooxygenase (COX) -1 and COX-2</sc>
###xml 124 127 124 127 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">(1)</xref>
###xml 184 187 184 187 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">(2)</xref>
###xml 403 406 403 406 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">(3)</xref>
###xml 447 448 447 448 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 622 625 622 625 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">(4)</xref>
###xml 850 853 850 853 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">(5)</xref>
###xml 1000 1003 1000 1003 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">(6)</xref>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 179 183 <span type="species:ncbi:10090">mice</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 991 999 <span type="species:ncbi:9606">patients</span>
Cyclooxygenase (COX) -1 and COX-2 are coexpressed in the airways of healthy individuals, as well as in patients with asthma (1). Inhibition of COX enhances bronchoconstriction in mice (2). Furthermore, in a subgroup of patients with asthma, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) induce bronchoconstriction and acute asthma, resulting in the "aspirin-sensitive asthma" condition (3). It is thought that prostaglandin (PG) E2, a product of COX, acts on prostaglandin E (EP) receptors on mast cells in the airways, providing a physiological brake against activation and histamine/leukotriene release (4). Thus, when aspirin and other NSAIDs are taken, COX is inhibited, the brake is removed, and airways are hypersensitive to antigens. Asthma is a chronic inflammatory disease in which COX-2 levels within the lung are elevated (5). Interestingly, despite COX-2 being present in the lung, COX-2 selective drugs, such as rofecoxib (Vioxx), do not induce asthma in these patients (6). This then presents the field with an anomaly-why do COX-2-selective drugs not induce asthma?
###end p 4
###begin p 5
###xml 129 132 129 132 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 133 137 <span type="species:ncbi:10090">mice</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
In the current study, we present novel and meaningful data that shed light on this important area. First, using tissue from COX-1-/- mice, we show that COX-1 is the functional isoform present in the airway with regard to bronchoconstriction. Second, using cells cultured from the airways of patients with aspirin-sensitive asthma, we show that despite detectable levels of COX-2, COX-1 is the functionally relevant form. Taken together, these observations provide a scientific rationale as to why COX-2 inhibitors are safe in asthma and illustrates a remarkably clear cut function of COX-1 in airway function.
###end p 5
###begin title 6
MATERIALS AND METHODS
###end title 6
###begin title 7
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and myograph studies
###end title 7
###begin p 8
###xml 9 12 9 12 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 128 131 128 131 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">(7)</xref>
###xml 138 141 138 141 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 524 525 518 519 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 530 531 524 525 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 598 599 592 593 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 613 614 607 608 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 630 631 624 625 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 642 643 636 637 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 645 646 639 640 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 719 722 713 716 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">(8)</xref>
###xml 13 17 <span type="species:ncbi:10090">mice</span>
###xml 142 146 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 318 322 <span type="species:ncbi:10090">Mice</span>
The COX-1-/- mice used in this study had an insertion into intron 11, resulting in transcription of an inactive "COX-1" protein (7). COX-1-/- mice were backcrossed for more than 7 generations onto a C57BL6 background. C57BL6 mice were used as wild-type controls. Male mice of 12-16 wk of age were used for this study. Mice were killed by cervical dislocation, before lungs were removed and dissected clear of connective tissue. Segments of main bronchi were loaded into wire myographs in warmed (37degreesC) and gassed (95%O2:5%CO2) physiological salt solution (PSS; NaCl, 119 mM; KCl, 4.7 mM; CaCl2, 2.5 mM; MgSO4, 1.17 mM; NaHCO3, 25 mM; KH2PO4, 1.18 mM; EDTA, 0.027 mM; and glucose, 5.5 mM), as described previously (8). Isometric tension was initially calibrated to 0 mN. Optimal tensions for each bronchus were established by performing standard-length tension responses. In brief, bronchi were sequentially stretched by 0.25-mN increments (passive tension) and stimulated to contract actively (active tension) by the additions of a depolarizing concentration of potassium (124 mM). Optimal tension was taken at the point at which increased stretch ceased to increase active tension. Bronchi were then allowed to equilibrate for 20 min in PSS. Tissues were subjected to increasing concentrations of either acetylcholine or U46619, and tensions were recorded. In some experiments, NSAIDs or vehicle (dimethyl sulfoxide) were added for 30 min prior to the addition of acetylcholine or U46619.
###end p 8
###begin title 9
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tissue
###end title 9
###begin p 10
###xml 471 474 471 474 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">(9)</xref>
###xml 561 562 558 559 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 705 709 702 706 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">(10)</xref>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 1112 1116 <span type="species:ncbi:9913">calf</span>
All subjects in the aspirin-sensitive asthma group had a history of aspirin-induced reaction, in that they developed a respiratory-type reaction following aspirin or NSAID ingestion. The reactions included bronchospasm, coughing, wheezing, and shortness of breath, as well as upper airway symptoms of rhinorrhoea and nasal obstruction. These patients had their aspirin sensitivity confirmed by an intranasal challenge with lysine-aspirin, as we have described previously (9). All patients (except for one) were receiving regular inhaled corticosteroids and beta2 adrenoreceptor stimulants, for use as required. Nasal polyp tissue was removed as part of outpatient surgery, as we have described previously (10). Tissue was dissected to remove the core inflammatory cell component, which is easily dissociated from surrounding stromal tissue and consists of inflammatory cells, including leukocytes and mast cells. Once the inflammatory core was removed the stromal airway tissue was chopped into small pieces and placed in to culture flasks containing DMEM supplemented with penicillin-streptomycin and 10% fetal calf serum. Cells began to grow out of the explants after 2-3 wk. Cells were fibroblast-like in appearance. Cells were plated into individual wells of either 96- or 6-well culture plates and grown in supplemented medium until confluent. For some experiments, cells were incubated with interleukin 1beta (IL-1beta; 1 ng/ml) for 24 h.
###end p 10
###begin title 11
Measurement of COX activity and protein expression
###end title 11
###begin p 12
###xml 188 190 188 190 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 343 344 343 344 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 386 390 386 390 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">(11)</xref>
###xml 528 532 528 532 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">(12)</xref>
###xml 543 547 543 547 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">(13)</xref>
###xml 522 527 <span type="species:ncbi:9606">human</span>
###xml 537 542 <span type="species:ncbi:10090">mouse</span>
###xml 682 687 <span type="species:ncbi:9606">human</span>
###xml 744 749 <span type="species:ncbi:10090">mouse</span>
###xml 783 787 <span type="species:ncbi:9925">goat</span>
At the beginning of the experiment, cells were incubated with a range of concentrations of aspirin, SC560, or rofecoxib for 30 min before the addition of the calcium ionophore A23187 (3x10-5M) and incubation for a further 30 min. Medium was then removed, and COX activity over the incubation period was determined by measuring the level of PGE2 within the medium using radioimmunoassay (11). COX protein expression was determined by Western blot analysis using the same protocol and antibodies as described previously for human (12) and mouse (13) tissues. beta-Actin levels were estimated on blots previously probed for COX-1 or COX-2 using a monoclonal primary antibody raised to human beta-actin peptide, detected by a secondary antibody to mouse immunoglobulin G (IgG) raised in goat (Abcam, Cambridge, UK).
###end p 12
###begin title 13
RESULTS
###end title 13
###begin title 14
###xml 22 28 <span type="species:ncbi:10090">murine</span>
COX-1 predominates in murine airway and mediates the prostaglandin brake to bronchoconstriction
###end title 14
###begin p 15
###xml 76 82 76 82 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 1</bold>
###xml 76 82 76 82 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig"><bold>Fig. 1</bold></xref>
###xml 123 124 121 122 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 182 185 180 183 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 232 233 228 229 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 337 340 333 336 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">(7)</xref>
###xml 422 425 418 421 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 431 439 427 435 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">(Fig. 1)</xref>
###xml 472 475 468 471 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 546 548 542 544 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 556 558 552 554 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;6</sup>
###xml 562 568 558 564 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 2</bold>
###xml 562 569 558 565 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig"><bold>Fig. 2</bold>A</xref>
###xml 591 593 587 589 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;8</sup>
###xml 601 603 597 599 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 612 613 608 609 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 606 613 602 609 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 666 669 662 665 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 810 812 806 808 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 831 833 827 829 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 854 856 850 852 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 915 921 911 917 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 3</bold>
###xml 915 924 911 920 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig"><bold>Fig. 3</bold>A&#8211;C</xref>
###xml 945 951 941 947 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 4</bold>
###xml 945 954 941 950 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig"><bold>Fig. 4</bold>A&#8211;C</xref>
###xml 1004 1007 1000 1003 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1114 1115 1110 1111 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1116 1117 1112 1113 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1108 1117 1104 1113 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">Fig. 3<italic>D</italic>&#8211;<italic>F</italic></xref>
###xml 1143 1144 1139 1140 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1145 1146 1141 1142 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1137 1146 1133 1142 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">Fig. 4<italic>D</italic>&#8211;<italic>F</italic></xref>
###xml 23 27 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 670 674 <span type="species:ncbi:10090">mice</span>
###xml 740 744 <span type="species:ncbi:10090">mice</span>
###xml 1008 1012 <span type="species:ncbi:10090">mice</span>
Bronchi from wild-type mice contained predominantly COX-1 immunoreactivity (Fig. 1; 87.2+/-9.6% of COX-1 positive control; n=4). COX-1 immunoreactivity persisted in tissue from COX-1-/- mice (86.5+/-18.3% of COX-1 positive control; n=3), most likely explained by the presence in tissue from these mice of a nonfunctional protein product (7). No COX-2 immunoreactivity was detected in bronchi from either wild-type or COX-1-/- mice (Fig. 1). Bronchi from wild-type or COX-1-/- mice contracted in response to increasing concentrations of U46619 (10-9 to 3x10-6 M; Fig. 2A) or acetylcholine (10-8 to 3x10-4M; Fig. 2B). For both agonists, responses in bronchi from COX-1-/- mice were increased compared to those in bronchi taken from wild-type mice. Pretreatment of bronchi from wild-type animals with naproxen (10-4 M), diclofenac (10-5 M), or ibuprofen (10-5 M) increased bronchoconstrictor responses to both U46619 (Fig. 3A-C) and acetylcholine (Fig. 4A-C). In contrast, pretreatment of bronchi from COX-1-/- mice with ibuprofen or naproxen had no significant effect on contractions induced by either U46619 (Fig. 3D-F) or acetylcholine (Fig. 4D-F).
###end p 15
###begin title 16
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Relation between COX-1 and COX-2 in nasal airway tissue from aspirin-tolerant and aspirin-sensitive patients
###end title 16
###begin p 17
###xml 299 305 299 305 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 5</bold>
###xml 299 306 299 306 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig"><bold>Fig. 5</bold>A</xref>
###xml 357 361 357 361 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">e.g.</italic>
###xml 368 371 368 371 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">(12</xref>
###xml 371 376 371 376 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">, 14)</xref>
###xml 390 394 390 394 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">(15)</xref>
###xml 419 423 419 423 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">(16)</xref>
###xml 521 522 518 519 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 515 522 512 519 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 620 621 617 618 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 650 651 647 648 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 644 651 641 648 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 715 716 712 713 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 804 805 801 802 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 798 805 795 802 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 936 937 930 931 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 942 943 936 937 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1081 1082 1072 1073 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1075 1082 1066 1073 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 34 40 <span type="species:ncbi:10090">murine</span>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 283 290 <span type="species:ncbi:9606">patient</span>
###xml 344 349 <span type="species:ncbi:9606">human</span>
###xml 748 755 <span type="species:ncbi:9606">patient</span>
Similar to observations made with murine airway tissues, cells cultured from nasal polyps obtained from aspirin-sensitive or aspirin-tolerant patients contained predominantly COX-1 protein. However, although in limited amounts, COX-2 immunoreactivity was detected in cells from both patient groups (Fig. 5A). In contrast to some other types of human cells [e.g., A549 (12, 14), endothelial (15), vascular smooth muscle (16)], the cytokine IL-1beta did not induce increased expression of COX-2 in nasal polyp cells (Fig. 5A). Cells cultured from control and aspirin-sensitive individuals released detectable levels of PGE2 over 24 h in culture (Fig. 5B). There was no significant difference in absolute levels of PGE2 released by cells from the two patient groups cultured under control conditions (Fig. 5B). Despite having little or no effect on protein expression, treatment of cells with IL-1beta for 24 h increased the release of PGE2. PGE2 release after IL-1beta was significantly higher from cells cultured from aspirin-sensitive than from aspirin-tolerant individuals (Fig. 5B).
###end p 17
###begin title 18
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Pharmacological characterization of COX isoforms in nasal airway tissue from aspirin-tolerant and aspirin-sensitive patients
###end title 18
###begin p 19
###xml 119 125 119 125 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Fig. 6</bold>
###xml 119 126 119 126 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig"><bold>Fig. 6</bold>A</xref>
###xml 175 176 175 176 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 169 176 169 176 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">Fig. 6<italic>B</italic></xref>
###xml 402 403 402 403 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 500 501 500 501 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 494 501 494 501 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">Fig. 6<italic>C</italic></xref>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 270 277 <span type="species:ncbi:9606">patient</span>
COX activity in human cells cultured from aspirin-sensitive and aspirin-tolerant individuals was inhibited by aspirin (Fig. 6A) and the COX-1 selective inhibitor SC560 (Fig. 6B). The potency and efficacy of aspirin and SC560 was identical in cells cultured from the two patient groups. In contrast to results with aspirin or SC560, the COX-2-selective drug rofecoxib was inactive as an inhibitor of PGE2 production in cells derived from both aspirin-sensitive and aspirin-tolerant individuals (Fig. 6C).
###end p 19
###begin title 20
DISCUSSION
###end title 20
###begin p 21
###xml 613 616 613 616 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">(6)</xref>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
Asthma is a chronic inflammatory disease characterized by inflammation of the airways and enhanced bronchoconstrictor responses. COX-1 and COX-2 are expressed in the airways of patients with asthma. However, unlike some other chronic inflammatory diseases, such as arthritis, inhibition of COX with NSAIDs does not provide any anti-inflammatory or analgesic relief in asthma. In fact, for a subset of patients with asthma, ingestion of NSAIDs induces asthma (aspirin-sensitive responders). Paradoxically, while NSAIDs induce asthma in sensitive individuals, selective COX-2 inhibitors appear to be well tolerated (6).
###end p 21
###begin p 22
###xml 463 464 463 464 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 602 606 602 606 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B17" ref-type="bibr">(17)</xref>
###xml 1027 1030 1027 1030 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 1423 1427 1423 1427 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">(18)</xref>
###xml 1771 1774 1771 1774 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 128 132 <span type="species:ncbi:10090">mice</span>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 973 978 <span type="species:ncbi:10090">mouse</span>
###xml 1031 1035 <span type="species:ncbi:10090">mice</span>
###xml 1485 1490 <span type="species:ncbi:10090">mouse</span>
###xml 1775 1779 <span type="species:ncbi:10090">mice</span>
In the current study, we confirm what is already known about the effects of NSAIDs on airway responses in tissue from wild-type mice. Pretreatment of bronchi with NSAIDs consistently increased the bronchoconstrictor effects of the thromboxane mimetic U46619 or acetylcholine. NSAIDs increase bronchoconstrictor responses by two potential mechanisms, both of which involve inhibition of prostaglandin synthesis. First, prostaglandins produced by COX (including PGE2) functionally antagonize airway contraction and secondly tonically suppress the synthesis and release of bronchoconstrictor leukotrienes (17). NSAIDs inhibit both COX-1 and COX-2; it is, therefore, not possible to establish which isoform of COX predominates by the use of NSAIDs alone. Here, we found that airway tissue from laboratory mice contained predominantly COX-1, with no detectable COX-2 expression. In line with this, we found that the ability of NSAIDs to increase bronchoconstrictor responses in mouse airways was completely lost in tissue from COX-1-/- mice. Although this observation may, on the face of it, seem predictable from our studies on COX expression, it was essential to check. Low levels of COX-2 may have been strategically compartmentalized-and therefore difficult to detect by Western blot analysis. Alternatively, NSAIDs may have been affecting airway responses by non-COX-dependent mechanisms known to be active in some tissues (18). However, our data clearly and definitively show that in mouse airways, COX-1, and not COX-2, is the target for NSAID action. It is conceivable that disruption of the COX-1 gene could influence COX-2 expression as a compensatory mechanism. However, as in tissue from wild-type animals, we found no detectable COX-2 in airway samples from COX-1-/- mice.
###end p 22
###begin p 23
###xml 422 425 422 425 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">(5)</xref>
###xml 623 624 623 624 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 808 809 805 806 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1040 1041 1034 1035 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1223 1224 1217 1218 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1224 1228 1218 1222 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">(19)</xref>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
###xml 215 223 <span type="species:ncbi:9606">patients</span>
###xml 383 391 <span type="species:ncbi:9606">patients</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
###xml 973 981 <span type="species:ncbi:9606">patients</span>
In human airway tissue cultured from nasal polyps, we detected both COX-1 and COX-2. As was the case for mouse tissue, COX-1 predominated. This was true for tissue from non-aspirin-sensitive donors, as well as from patients with aspirin-sensitive asthma. These observations are consistent with others in the literature showing that both isoforms of COX are present in the airways of patients with aspirin-sensitive asthma (5). In our study, we went further, and investigated the functional capacity of COX in human airway cells and the COX isoform expressed. As expected, nasal polyp cells released detectable levels of PGE2 when stimulated with the calcium ionophore A23187. Interestingly, although activation of cells with IL-1beta did not induce COX-2 in these cells, it did increase the production of PGE2 by the cells. This was true for cells cultured from both aspirin-sensitive and control subjects. Interestingly, after incubation with IL-1beta, cells derived from patients with aspirin-sensitive asthma release higher levels of PGE2 than cells cultured from control donors. Clearly, this was not mediated by increased expression of COX and most likely, therefore, was due to increased expression of phospholipase A2(19), the enzyme responsible for liberation of the substrate arachidonic acid.
###end p 23
###begin p 24
###xml 193 196 193 196 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">(9)</xref>
###xml 385 388 385 388 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">(11</xref>
###xml 388 393 388 393 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">, 20)</xref>
###xml 450 454 450 454 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B21" ref-type="bibr">(21)</xref>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 781 789 <span type="species:ncbi:9606">patients</span>
In a previous study from our group using blood donated by these patients, we found that COX-1 or COX-2 was similarly inhibited by NSAIDs, including aspirin, irrespective of aspirin sensitivity (9). In the current study, we found that airway cells from aspirin-sensitive and aspirin-tolerant donors were inhibited similarly by aspirin or by SC560. Aspirin inhibits both COX-1 and COX-2 (11, 20), whereas SC560 is a highly selective inhibitor of COX-1 (21). Again, as with aspirin, the potency and efficacy of SC560 were identical in cells from aspirin-sensitive and control donors. Finally, we found that, despite the presence of detectable levels of COX-2, the COX-2-selective inhibitor rofecoxib, was inactive as an inhibitor of COX in cells derived from either aspirin-sensitive patients or control donors.
###end p 24
###begin p 25
###xml 372 380 <span type="species:ncbi:9606">patients</span>
In summary, our findings using genetically modified animals and tissue from aspirin-sensitive individuals show that COX-1 is the dominant isoform in the airways, particularly with regard to mechanical function. Notably, these data explain why aspirin and other NSAIDs that inhibit COX-1, but not drugs that selectively inhibit COX-2, can be tolerated by aspirin-sensitive patients with asthma.
###end p 25
###begin p 26
This research was supported by the Wellcome Trust, European Community FP6 funding (Eicosanox; LSHM-CT-2004-0050333), European Community FP7 funding (Marie Currie Fellowship) and the Spanish Government. This publication reflects only the authors' views. The European Community is not liable for any use that may be made of information herein.
###end p 26
###begin article-title 27
Expression of cyclo-oxygenase 1 and 2 proteins in upper respiratory mucosa
###end article-title 27
###begin article-title 28
Cholinergic contraction is altered in nNOS knockouts
###end article-title 28
###begin article-title 29
Aspirin-sensitive rhinosinusitis and asthma
###end article-title 29
###begin article-title 30
###xml 107 115 <span type="species:ncbi:9606">patients</span>
Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients
###end article-title 30
###begin article-title 31
Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma
###end article-title 31
###begin article-title 32
Safety of a specific COX-2 inhibitor in aspirin-induced asthma
###end article-title 32
###begin article-title 33
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
###end article-title 33
###begin article-title 34
Pharmacology of airways and vessels in lung slices in situ: role of endogenous dilator hormones (Online)
###end article-title 34
###begin article-title 35
Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors
###end article-title 35
###begin article-title 36
High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics
###end article-title 36
###begin article-title 37
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
###end article-title 37
###begin article-title 38
Cellular mechanisms of acetaminophen: role of cyclo-oxygenase
###end article-title 38
###begin article-title 39
###xml 159 162 <span type="species:ncbi:10116">rat</span>
Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues
###end article-title 39
###begin article-title 40
###xml 47 52 <span type="species:ncbi:9606">human</span>
Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone
###end article-title 40
###begin article-title 41
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human cyclooxygenase-2 cDNA
###end article-title 41
###begin article-title 42
###xml 33 38 <span type="species:ncbi:9606">human</span>
Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery
###end article-title 42
###begin article-title 43
Mechanisms of aspirin sensitivity
###end article-title 43
###begin article-title 44
Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy
###end article-title 44
###begin article-title 45
Interleukin-1 beta induces cytosolic PLA2 in parallel with prostaglandin E2 in rheumatoid synovial fibroblasts
###end article-title 45
###begin article-title 46
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
###end article-title 46
###begin article-title 47
Pharmacological analysis of cyclooxygenase-1 in inflammation
###end article-title 47
###begin article-title 48
Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events
###end article-title 48
###begin article-title 49
Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid
###end article-title 49
###begin p 50
###xml 135 136 135 136 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 174 175 174 175 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 231 235 231 235 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">(22)</xref>
###xml 283 287 283 287 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">(11)</xref>
###xml 486 489 483 486 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 83 88 <span type="species:ncbi:10090">mouse</span>
###xml 450 454 <span type="species:ncbi:10090">mice</span>
###xml 490 494 <span type="species:ncbi:10090">mice</span>
###xml 562 566 <span type="species:ncbi:10090">mice</span>
Western blot analysis of COX immunoreactivity in mouse bronchi. Tissue extracts of mouse bronchi contained immunoreactivity for COX-1 (A) with little or no detectable COX-2 (B). Positive (+ve) controls were extracts of MEG01 cells (22) for COX-1 and LPS-stimulated J774 cell extract (11) for COX-2. Blots were subjected to immune staining for beta-actin as an indicator of protein loaded. Lane 1, positive control; lanes 2, 3, bronchi from wild-type mice; lanes 4, 5, bronchi from COX-1-/- mice. Similar results were obtained using tissue from a total of 3 or 4 mice.
###end p 50
###begin p 51
###xml 53 54 53 54 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 79 80 79 80 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 132 135 132 135 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 176 178 174 176 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">se</sc>
###xml 180 181 178 179 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 208 209 206 207 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:10090">mice</span>
Comparison of bronchoconstriction induced by U46619 (A) or acetylcholine (ACh; B) in airways from wild-type (solid circles) or COX-1-/- (open circles) mice. Data are means +/- se; n = 5 mice; 2-way ANOVA. ***P < 0.001.
###end p 51
###begin p 52
###xml 59 60 59 60 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 61 62 61 62 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 72 73 72 73 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 74 75 74 75 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 218 220 218 220 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 239 241 239 241 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 263 265 263 265 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 294 296 292 294 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">se</sc>
###xml 298 299 296 297 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 338 339 336 337 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Effect of NSAIDs on bronchoconstriction induced by U46619 (A-C) or ACh (D-F) in airway tissue from wild type mice. The effects of the following NSAIDs were tested on constrictor responses to U46619 or ACh; naproxen (10-4 M), diclofenac (10-5 M), and ibuprofen (10-5 M). Responses are means +/- se; n = 4 or 5 experiments; 2-way ANOVA. ***P < 0.001.
###end p 52
###begin p 53
###xml 60 63 60 63 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A&#8211;C</italic>
###xml 73 76 73 76 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">D&#8211;F</italic>
###xml 105 108 105 108 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 220 222 220 222 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 241 243 241 243 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 265 267 265 267 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;4</sup>
###xml 296 298 294 296 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">se</sc>
###xml 303 304 301 302 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 370 371 368 369 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 109 113 <span type="species:ncbi:10090">mice</span>
Effect of NSAIDs on bronchoconstrictions induced by U46619 (A-C) or ACh (D-F) in airway tissue from COX-1-/- mice. The effects of the following NSAIDs were tested on constrictor responses to U46619 or ACh of naproxen (10-5 M), diclofenac (10-5 M), and ibuprofen (10-4 M). Responses are means +/- se for n = 4 or 5 experiments; 2-way ANOVA. ns, nonsignficant difference (P>0.05).
###end p 53
###begin p 54
###xml 416 420 406 410 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">(22)</xref>
###xml 485 489 472 476 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">(23)</xref>
###xml 539 540 526 527 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 589 591 576 578 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 607 608 594 595 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 630 632 615 617 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">se</sc>
###xml 634 635 619 620 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 783 791 768 776 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">post hoc</italic>
###xml 799 800 784 785 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
Relative levels of COX-1 and COX-2 expressed in human cells derived from control (no aspirin sensitivity) and aspirin-sensitive donors and cultured under control conditions or in the presence of IL-1beta for 24 h. COX-1 and COX-2 immunoreactivity was detected in extracts from control cells and those treated with IL-1beta (Alpha). Positive controls used for this blot were MEG-01 cytosol, which contains only COX-1 (22), and A549 cells treated with IL-1beta, which express only COX-2 (23). COX activity in cells measured by release of PGE2 into the medium after incubation with A23187 (10-5 M) for 30 min (B). Data are means +/- se; n = 15 experiments (cells from at least 3 different patients; experiments performed in triplicate on at least 5 experimental days); 1-way ANOVA with post hoc test. *P < 0.05.
###end p 54
###begin p 55
###xml 19 20 19 20 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 30 31 30 31 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 48 49 48 49 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 170 172 168 170 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">se</sc>
###xml 174 175 172 173 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Effect of aspirin (A), SC560 (B), or rofecoxib (C) on COX activity in cells from control (solid squares) or aspirin-sensitive patients (open squares). Data are means +/- se; n = 15 experiments (cells from at least 3 different patients; experiments performed in triplicate on at least 5 experimental days).
###end p 55

